Intratumoral Heterogeneity as a Therapy Resistance Mechanism
Authors:
- Jessie VillanuevaJVJessie Villanueva
- Meenhard HerlynMHMeenhard Herlyn
- 1 January 2012
- book chapter
- Published by Elsevier
- Vol. 65, 335-359
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Targeting CD20 in Melanoma Patients at High Risk of Disease RecurrenceMolecular Therapy, 2012
- Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?Molecular Therapy, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor GrowthCell, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K SignalingCancer Cell, 2009
- Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinomaClinical & Experimental Metastasis, 2009
- Increased expression of stem cell markers in malignant melanomaLaboratory Investigation, 2007
- Mutations of the BRAF gene in human cancerNature, 2002